IgG4-RD can arise in various organs, causing fibrosis and irreversible organ damage. Understanding how organ damage occurs is key to making an accurate diagnosis of IgG4-RD.
FDA Approval
In order to help hemophiliacs regain hemostasis, Qfitlia helps boost thrombin production by decreasing AT, a protein that prevents blood clotting.
The first medication approved by the FDA to treat CTX, a rare lipid storage condition, is Ctexli.
The U.S. Food and Drug Administration (FDA) has approved GOMEKLI™ (mirdametinib), SpringWorks Therapeutics, Inc.’s MEK inhibitor, for the treatment of adult and pediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection. SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company […]
Data from this 28-country multi-institutional effort helped the Food and Drug Administration (FDA) approve this combination more quickly in December 2024, giving patients with BRAF V600E-mutant mCRC a new and effective first-line treatment choice.
Teri Boudreaux is thankful for the time she gets to spend with her family, whether it’s hiking, playing with her grandkids, travelling with her spouse, lounging on the beach, or taking up new interests like pickleball. She has survived breast cancer twice. In spite of everything, though, she still harbours […]
